Messaging Response Times

What you are actually buying

A telehealth subscription bundles four things that are frequently priced as one: a clinical review, a prescription, fulfilment through a pharmacy, and ongoing access to somebody who will answer a question. Programmes differ enormously in how much of each they provide, and the difference is invisible in a monthly price.

The question that separates care from a vending machine

Can this programme decline to prescribe? A service that guarantees approval before a clinician has seen your history is not running a clinical process, whatever else it discloses. The most reassuring thing a telehealth service can do is turn someone away.

What the care model changes about your bill

Video visits, included laboratory work and real clinician access cost money to provide, and programmes that provide them are rarely the cheapest. That is not a scandal — it is what you are paying for. The failure is paying a premium for an asynchronous questionnaire that a cheaper programme provides identically.

What we could not verify

Response times, whether the same clinician sees you twice, and how a programme behaves when something goes wrong. We hold no measurements of those we would defend, so they are absent from every table rather than estimated.

What a subscription actually buys

Four things, usually priced as one: a clinical review, a prescription, fulfilment through a pharmacy, and ongoing access to somebody who will answer a question. Programmes differ enormously in how much of each they provide, and the difference is invisible in a monthly price.

The most expensive programmes are not reliably the ones providing the most. Some are simply carrying more marketing cost, and a cheaper programme that names its pharmacy and answers messages within a day is providing more of what matters.

The test that separates care from a vending machine

Can this programme decline to prescribe? A service that guarantees approval before a clinician has seen your history is not running a clinical process, whatever else it discloses. The most reassuring thing a telehealth service can do is turn somebody away.

Ask what histories would stop a prescription being written. A programme that can answer has clinical governance; one that treats the question as an obstacle does not.

Where asynchronous care is genuinely adequate

For an uncomplicated patient with a clear history, a well-designed questionnaire reviewed by a licensed clinician is a reasonable standard of care and is how a large share of prescriptions in this category are written. It is faster, cheaper and no less careful when the intake is designed to surface contraindications.

It is weaker where the history is complicated, where the answers need follow-up questions, or where somebody is likely to under-report. A video visit is not automatically better care, but it is harder to complete on autopilot.

How this connects to what you will actually pay

Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 16 programmes we price, that runs from $215 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.

5 of those programmes charge a recurring platform fee on top of medication and 12 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.

What we could verify and what we could not

11 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.

Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.

The regulatory distinction that sits under all of this

Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.

That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.

Why titration is a pricing question

Tirzepatide is started at 2.5 mg weekly and increased in 2.5 mg steps at intervals of at least four weeks. The starter dose is a tolerance-building dose rather than a therapeutic one, and the gastrointestinal effects that cause most discontinuation cluster in the days after each increase.

Reaching a maintenance dose therefore takes at least eight to twelve weeks when nothing is repeated, and repeats are common rather than exceptional. Most of a first year is spent at or near maintenance, which is why every figure on this site is stated at 10 mg and why 12 of the 16 priced programmes holding one price across the ladder is a materially different offer from the rest.

The molecule, and why it costs more than semaglutide

Tirzepatide is a single peptide that activates two incretin receptors: GLP-1, which semaglutide also targets, and GIP, which it does not. Both receptors influence insulin secretion, gastric emptying and central appetite signalling, and the working hypothesis for the larger effect size is that engaging both produces effects the GLP-1 arm alone does not.

That dual action is also part of why it costs more to make. The peptide is longer and more structurally complex than semaglutide, the synthesis is harder, and the active pharmaceutical ingredient sells at a premium to compounding pharmacies. Across programmes carrying both molecules, tirzepatide typically runs forty to a hundred per cent above the same programme's semaglutide price.

The commercial consequence is that a compounded tirzepatide programme has less room to discount than a compounded semaglutide one. When a tirzepatide price looks dramatically below the market, the explanation is usually a promotional rate, a prepaid term or a starting dose rather than a cheaper supply chain.

What the head-to-head trial actually showed

SURMOUNT-5 randomised adults with obesity to tirzepatide or semaglutide and reported a larger mean reduction in body weight on tirzepatide over 72 weeks. It is the strongest direct comparison available and it is the reason many people arrive at this molecule specifically rather than at GLP-1 therapy in general.

Three caveats are worth carrying. A mean is not a prediction for an individual, and the distribution around it is wide. Trial participants received structured support most telehealth programmes do not replicate. And the trial compared maximum tolerated doses, which is a different question from what a given person will tolerate.

Read as a purchasing decision, it says the more expensive molecule does more on average. It does not say it will do more for you, and it says nothing about which programme should supply it.